Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit

v3.8.0.1
Stockholders' Deficit
3 Months Ended
Mar. 31, 2018
Equity [Abstract]  
Stockholders' Deficit

Note 10 – Stockholders’ Deficit

 

Preferred Stock

 

The Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of March 31, 2018, the Company had outstanding shares of preferred stock consisting of shares of its Series I-1 Preferred Stock, shares of Series I-2 Preferred Stock, 215 shares of its Series G Preferred Stock, 60 shares of its Series H Preferred Stock and 1,750,000 shares of its Series F Convertible Preferred Stock.

 

The rights of Preferred F, G, H, I-1 and I-2 shares are disclosed in the 2017 10K. There are no changes in these rights.

 

Common Stock

 

The Company had 499,992,133 and 19,750,844 shares of common stock issued and outstanding at March 31, 2018 and December 31, 2017, respectively. The Company issued 480,249,156 shares of its common stock during the three months ended March 31, 2018 as follows:

 

During the three months ended March 31, 2018, the Company issued an aggregate of 333,315,823 shares of its common stock upon conversion of $3.1 million of the principal amount of the March 2017 Debentures.

 

During the three months ended March 31, 2018, the Company issued 75,600,000 shares of common stock upon exercise of 119,746,776 March 2017 Series B Warrants, on a cashless basis.

 

During the three months ended March 31, 2018 the Company issued an aggregate of 71,333,333 shares of restricted stock as described below.

 

Restricted Stock

 

On August 14, 2017, the Board of Directors, based on the recommendation of the Compensation Committee of the Board and in accordance with the provisions of the 2007 Equity Plan, approved grants to employees and directors of the Company of an aggregate of 181,933 shares of restricted common stock of the Company. The grants fully vest on the first anniversary of the date of grant, subject to the grantee’s continued status as an employee or director, as the case may be, on the vesting date. During the three months ended March 31, 2018, 2,493 shares of the restricted stock were forfeited by their terms and returned to treasury.

 

On March 6, 2018, the Company issued an aggregate of 71,333,333 shares of restricted stock to employees and directors, based upon the recommendation of the Compensation Committee of the Board. The grants fully vested immediately. The Company recognized stock-based compensation in the amount of $477,933 for the grant of such restricted stock based on a valuation of $.0067 per share.

 

Stock Options

 

The following table summarizes the Company’s stock option activity for the three months ended March 31, 2018:

 

    Number of
options
    Weighted-
average 
exercise 
price
    Weighted-
average contractual
term (Yrs.)
 
Outstanding at December 31, 2017     38,478     $ 2,072.75       8.33  
Granted     -       -          
Expired     -       -          
Forfeit             -          
Exercised     -       -          
Outstanding at March 31, 2018     38,478     $ 2,072.75       8.33  
Exercisable at March 31, 2018     32,922     $ 2,373.16          

 

As of March 31, 2018, the Company had approximately $0.1 million of unrecognized compensation cost related to stock options granted under the Company’s 2007 Equity Plan, which is expected to be recognized over a weighted-average period of 0.94 years.

 

Warrants

 

The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s common stock. The following summarizes the information related to warrants issued and the activity during the three months ended March 31, 2018:

 

    Number of warrants     Weighted
average 
exercise price
 
Balance at December 31, 2017     2,176,403,218     $ 0.0444  
Warrants issued during the period     -     $ -  
Increases due to dilution     13,411,976,939     $ -  
Warrants exercised during the period     (119,746,776 )   $ 0.0038  
Warrants expired during the period     -     $ -  
Balance at March 31, 2018     15,468,633,381     $ 0.0062  

 

Basic and Diluted Loss per Share

 

Basic loss per share excludes dilution and is computed by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company. For the three months ended March 31, 2018 and 2017, basic loss per share is the same as diluted loss per share.

 

Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. As of March 31, 2018 and 2017, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:

 

    As of March 31,  
    2018     2017  
Warrants     15,468,633,381       30,595,665  
Convertible preferred stock     893,098,291       595,556  
Convertible debt     781,485,502       10,007,141  
Stock options     38,478       709,025  
      17,143,255,652       41,907,387